Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck dissolves Simcere JV amid rapid China changes

This article was originally published in Scrip

Executive Summary

Once hailed as the model for global going local in China, a joint venture created merely three years ago between Merck and Simcere has quietly faded into history. Does the move signal that the JV model is not working in China?

You may also be interested in...



Can An Elephant Crack China’s Bamboo Ceiling For Generics?

Among the many challenges facing foreign generics firms operating in China, dealing with ever-tightening policies and regulations is probably the toughest, and has already forced several multinationals to quit the market. But one Indian joint venture is looking to effectively exploit targeted niche opportunities.

Can An Elephant Crack China’s Bamboo Ceiling For Generics?

Among the many challenges facing foreign generics firms operating in China, dealing with ever-tightening policies and regulations is probably the toughest, and has already forced several multinationals to quit the market. But one Indian joint venture is looking to effectively exploit targeted niche opportunities.

Trump Or Biden, China Determined To Narrow Health Gap With US

Regardless of who wins, China seems to be looking beyond the 3 November US General Election, instead pouring in large resources to elevate its domestic health sector on a par with international standards, creating opportunities and profoundly impacting many areas from novel therapy development to investment decisions.

Topics

Related Companies

UsernamePublicRestriction

Register

MT142578

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel